Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo
V. Alvarez(Harvard University), Zheng‐Yi Chen(Massachusetts Eye and Ear Infirmary), Arun Prabhu Rameshbabu(Massachusetts Eye and Ear Infirmary), Xue Gao(Xijing Hospital), Yong Tao(Shanghai Ninth People's Hospital), Wenliang Zhu(Kyoto Institute of Technology), John A. Zuris(Howard Hughes Medical Institute), Wan Du(University of Michigan), Weijia Kong(Wuhan Union Hospital), Johnny H. Hu(Howard Hughes Medical Institute), Benjamin P. Kleinstiver(Harvard University), Yilai Shu(Fudan University), Yiran Li(Morinaga (Japan)), David Liu(University of Louisville), David B. Thompson(Howard Hughes Medical Institute), Madelynn N. Whittaker(Cardiovascular Institute of the South), Xueazhong Liu(University of Miami), Hao Wu(Shanghai Jiao Tong University)
Cited by 0
Related Papers
High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects
|Nature|2016|2.7k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
|Nature|2015|1.7k
Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
|Nature Biotechnology|2014|1.5k